Lilly’s Lartruvo Withdrawal Stirs Questions About Payment For Accelerated Approval Drugs
Executive Summary
News that the soft tissue sarcoma drug will come off the market after its confirmatory trial failed to verify clinical benefit spurs Memorial Sloan-Kettering’s Peter Bach to ask whether Lilly will refund money to payers.
You may also be interested in...
BIO 2019 Notebook: M&A Soars, Lartruvo Lookback, BIO Vs. ASCO
News and views from day four of the BIO International Convention: emerging company M&A deals nearly double in 2018; former FDA official Amy McKee said "everything worked right" with accelerated approval and removal of Lilly's Lartruvo; and the ASCO effect on the 3-6 June BIO meeting.
BIO 2019 Notebook: Lartruvo Lookback, M&A Soars, BIO Vs. ASCO
News and views from day four of the BIO International Convention: Former FDA official Amy McKee said "everything worked right" with accelerated approval and removal of Lilly's Lartruvo; emerging company M&A deals nearly double in 2018; and the ASCO effect on the 3-6 June BIO meeting.
Lartruvo Could Be A Failure Of The Drug, The Design Or The Disease
The presentation of the ANNOUNCE results, the failed confirmatory trial for Lilly’s Lartruvo, at ASCO re-opened questions about the accelerated approval and the appropriate way to study soft tissue sarcoma.